NCT03898011View on ClinicalTrials.gov

A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 23, 2019

Primary Completion Date

May 4, 2019

Study Completion Date

May 4, 2019

Conditions
Healthy Adults
Interventions
DRUG

Lamotrigine

Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus

DRUG

Lamictal

Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia

Trial Locations (1)

150010

"State Autonomous Healthcare Facility of the Yaroslavl Region Clinical Hospital No. 2", Yaroslavl

All Listed Sponsors
collaborator

ClinPharmInvest, LLC

OTHER

lead

Pharmtechnology LLC

INDUSTRY

NCT03898011 - A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting Conditions | Biotech Hunter | Biotech Hunter